INVESTOR RELATIONS

Track all markets on TradingView

SCINAI IMMUNOTHERAPEUTICS
(NASDAQ: SCNI)
COMPANY OVERVIEW

Scinai is a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bio-services business unit.

With over 20 years of experience in recombinant protein process development and cGMP manufacturing, Scinai is on a mission to elevate drug development. Every step of the way.

Our Business Units

Scinai operates with two complementing Business Units: R&D and CDMO Bioservices.

Featured
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Latest News

EVENTS

Sign up for news and updates

Sign up with your email address.

Q3 2024

LATEST FINANCIAL RESULTS

SEC

Analyst & Investor Webinar

ANNUAL REPORTS 2023

QUARTERLY REPORTS

Governance

Contact us